We fund clinical trials for all types of cancers and prioritize only the most cutting-edge research that can help patients today. Gateway invests in next generation of potential breakthroughs in patient-centric cancer research in order to drive transformational advances in cancer treatment.
How Gateway is Unique:
Gateway focuses exclusively on patient-centered cancer research that improves treatment outcomes and restores the cancer patients’ quality of life.
Since its inception over 24 years ago, Gateway has funded over 120 innovative cancer research clinical trials. New trials are continuously added in a rolling grant application process.
Sarah Leary, MD, University of Washington, Seattle Children’s Hospital
A phase I and expanded imaging study of BLZ-100 in pediatric patients with primary brain tumors)
Nagi Kumar, PhD, RD, Moffitt Cancer Institute
A Phase II clinical trial to ameliorate symptoms of cognitive impairment in women treated with chemotherapy for breast cancer: the COGNUTRIN trial)
Jane Winter, MD & Bryan Locke, MD, Northwestern University
Phase II: Study of pidilizumab in patients with diffuse large B-cell lymphoma following first remission)
Gateway only invests in Phase I and Phase II human clinical trials where true innovation and transformational discoveries happen. Phase I and II clinical trials are severely underfunded, yet have the greatest patient impact in conquering cancer.
It costs just $16.56 per patient per day in a Gateway-funded cancer clinical trial. Will you help us fund another day of research? Fund one day, one week or more!
Gateway for Cancer Research’s annual Cures Gala, one of Chicago’s premier social events, was treated to surprise performances by R&B Music Hall of Famers, The Chi-Lites and the Grammy Hall of Fame group, The Temptations. The performances helped boost donations to fund innovative cancer clinical trial research.
Director of Marketing & Development